Status:
AVAILABLE
Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)
Lead Sponsor:
Biohaven Pharmaceuticals, Inc.
Conditions:
SCA
Spinocerebellar Ataxias
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this expanded access protocol is to provide access to the investigational drug troriluzole in patients with spinocerebellar ataxia (SCA).
Detailed Description
This is an Intermediate-Size Patient Population Expanded Access Protocol designed to provide treatment use of troriluzole to patients with spinocerebellar ataxia (SCA) who are considered to be eligibl...
Eligibility Criteria
Inclusion
- Key
- Patient has a confirmed diagnosis of Spinocerebellar Ataxia (SCA), defined as either clinical evidence supporting diagnosis OR confirmed genotypic diagnosis.
- Adequate hepatic function.
- Key
Exclusion
- Patient is known to have acute or chronic liver disease that is clinically significant in the judgement of the Physician.
- Patient has a history of a clinically significant medical condition that would interfere with the patients ability to comply with the expanded access protocol or would place the patient at increased risk.
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT06034886
Last Update
January 9 2026
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.